CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade OXFORD BIOMEDICA PLC ORD 50P - OXB CFD

3.781
0%
Market Trading Hours* (UTC) Opens on Monday at 07:00

Mon - Fri: 07:00 - 15:30

  • Summary
  • Historical Data
Trading сonditions
Spread 0.178
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02461 %
Charges from full value of position ($-4.68)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02461%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002692 %
Charges from full value of position ($0.51)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002692%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency GBP
Margin 5.00%
Stock exchange United Kingdom of Great Britain and Northern Ireland
Commission on trade 0%

Key Stats
Prev. Close 3.781
Open 3.796
1-Year Change 26.15%
Day's Range 3.736 - 3.866
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 11, 2024 3.781 -0.015 -0.40% 3.796 3.866 3.736
Oct 10, 2024 3.781 -0.025 -0.66% 3.806 3.856 3.736
Oct 9, 2024 3.766 -0.055 -1.44% 3.821 3.836 3.761
Oct 8, 2024 3.796 0.060 1.61% 3.736 3.846 3.736
Oct 7, 2024 3.816 0.030 0.79% 3.786 3.886 3.726
Oct 4, 2024 3.776 0.030 0.80% 3.746 3.901 3.691
Oct 3, 2024 3.776 0.065 1.75% 3.711 3.816 3.706
Oct 2, 2024 3.776 0.135 3.71% 3.641 3.791 3.641
Oct 1, 2024 3.721 -0.025 -0.67% 3.746 3.796 3.676
Sep 30, 2024 3.656 -0.060 -1.61% 3.716 3.841 3.656
Sep 27, 2024 3.796 0.015 0.40% 3.781 3.866 3.696
Sep 26, 2024 3.711 0.115 3.20% 3.596 3.776 3.596
Sep 25, 2024 3.696 0.030 0.82% 3.666 3.741 3.586
Sep 24, 2024 3.661 0.045 1.24% 3.616 3.766 3.546
Sep 23, 2024 3.596 0.200 5.89% 3.396 3.596 3.396
Sep 20, 2024 3.431 0.040 1.18% 3.391 3.501 3.366
Sep 19, 2024 3.436 0.140 4.25% 3.296 3.501 3.266
Sep 18, 2024 3.311 -0.005 -0.15% 3.316 3.401 3.296
Sep 17, 2024 3.336 -0.020 -0.60% 3.356 3.481 3.296
Sep 16, 2024 3.496 0.185 5.59% 3.311 3.531 3.281

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Oxford BioMedica plc Company profile

About Oxford BioMedica plc

Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

Financial summary

BRIEF: For the six months ended 30 June 2021, Oxford BioMedica plc revenues increased from £34M to £81.3M. Net income totaled £18.1M vs. loss of £6.7M. Revenues reflect Europe segment increase from £19M to £70.3M. Net Income reflects Platform segment income totaling £24.4M vs. loss of £3.1M. Basic Earnings per Share excluding Extraordinary Items increased from -£0.09 to £0.22.

Equity composition

10/2003, Rights Issue, 27 new shs for every 50 shs held @ GBP 0.17 (Fct:1.54). 03/2001, Rights Issue, 1 new share for every 9 shs held @ GBP 0.55 (Fct:1.111111). 03/1998, Rights Issue, 1 new share for every 4 shs held @ GBP 0.10 (Fct:1.076). 05/2014, Priority Issue, 1 new shares for every 5 shares held @ GBp 2 (Factor:1).

Industry: Bio Therapeutic Drugs

Windrush Court
Transport Way
OXFORD
OXFORDSHIRE OX4 6LT
GB

News

S&P 500 expected to deliver modest earnings growth in Q3

Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.

12:40, 11 October 2024

US Core CPI tipped to remain unchanged in September

US inflation expectations are steady, with core CPI projected to remain at 3.2% for September while headline inflation moderates to its lowest level since February 2021. Despite the US Federal Reserve delivering a 50 basis point interest rate cut in September, stronger-than-expected job market data has raised concerns about sustained economic demand and inflation pressures.

07:10, 9 October 2024

RBNZ expected to deliver “jumbo” rate cut

The Reserve Bank of New Zealand is set to cut interest rates during its upcoming meeting, with expectations of either a 25 or 50 basis point reduction. This move follows a 25 basis point cut in August as the RBNZ responded to the country’s recessionary conditions and inflation concerns.

08:48, 8 October 2024

September Non-Farm Payrolls eases fears of US economic slowdown

Markets are reacting with a US Dollar surge and a potential trend reversal, highlighting the impact of robust economic activity outside of monetary policy influences.

07:44, 8 October 2024

Gold's recent story

Last week, we explored the key price drivers of gold, and how they impacted the price of the precious metal this year and last. Now, we’ll bring these factors to life in a chart, showing you ten instances the gold price responded to critical fundamental events, including central bank policies, global economic data, and geopolitical events.

15:36, 7 October 2024

September US Non-Farm Payrolls Preview

Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.

07:59, 2 October 2024

Market of the Month - Gold, an overview

In 2024, gold has been on an upward trajectory, hitting high after high as global markets face ongoing challenges. This precious metal, long seen as a safe haven, has been proving its worth, drawing attention from traders around the world as its bullish surge continues.

06:00, 30 September 2024

People also watch

XRP/USD

0.53 Price
-2.040% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

62,555.85 Price
-0.850% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

20,238.60 Price
-0.070% 1D Chg, %
Long position overnight fee -0.0248%
Short position overnight fee 0.0026%
Overnight fee time 21:00 (UTC)
Spread 7.0

Oil - Crude

75.01 Price
-0.100% 1D Chg, %
Long position overnight fee 0.0182%
Short position overnight fee -0.0401%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 650,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading